Pharmaco - Articles
27-Aug-2010
Start looking for a new role as soon as you know your role is at an end and the prospects internally for reassignment are limited. Even if you will get a redundancy package, it is easier to be re-employed if you have the shortest possible break.
When do I start looking? Start looking for a new role as soon as you know your role is at an end and the prospects internally for reassignment are limited. Even if you will get a redundancy package, it is easier to be re-employed if you have the shortest possible break. You can often negotiate a break prior to starting but get the job first! Market conditions are such that unless you have ‘alternate support’ gap periods are to be avoided. What do I need to do to my CV? First of all, look critically at your current CV. Are there any obvious mistake…
When do I start looking? Start looking for a new role as soon as you know your role is at an end and the prospects internally for reassignment are limited. Even if you will get a redundancy package, it is easier to be re-employed if you have the shortest possible break. You can often negotiate a break prior to starting but get the job first! Market conditions are such that unless you have ‘alternate support’ gap periods are to be avoided. What do I need to do to my CV? First of all, look critically at your current CV. Are there any obvious mistake…
Recent talks are about the recession, economic downturn, credit crunch and so on. However, the pharma giant Pfizer made a remarkable start in 2009.
London, UK - 29 January, 2009 - Recent talks are about the recession, economic downturn, credit crunch and so on. However, the pharma giant Pfizer made a remarkable start in 2009. Pfizer acquires its rival big pharma company Wyeth for about $68bn for stock and cash. This acquisition is said to be the one of the biggest in the pharmaceutical history. However, would it have been better for Pfizer to have acquired Amgen instead of Wyeth? Pfizer acquires Wyeth- Behind the Scene: Pfizer faces tough competition ahead, from generics after the expiry of its block buster drug Lipitor in 2011. Lipitor a cholesterol treatment drug, which generates around…
London, UK - 29 January, 2009 - Recent talks are about the recession, economic downturn, credit crunch and so on. However, the pharma giant Pfizer made a remarkable start in 2009. Pfizer acquires its rival big pharma company Wyeth for about $68bn for stock and cash. This acquisition is said to be the one of the biggest in the pharmaceutical history. However, would it have been better for Pfizer to have acquired Amgen instead of Wyeth? Pfizer acquires Wyeth- Behind the Scene: Pfizer faces tough competition ahead, from generics after the expiry of its block buster drug Lipitor in 2011. Lipitor a cholesterol treatment drug, which generates around…
27-Aug-2010
The speculation that started last year and then reappeared last week surrounding a possible major acquisition by Pfizer has come to a close.
The speculation that started last year and then reappeared last week surrounding a possible major acquisition by Pfizer has come to a close. This morning Pfizer announced that it plans to acquire Wyeth for $68 billion. There were several reasons why Pfizer would look to make an acquisition such as this. Two of these include Pfizer’s need to compensate for the impending patent loss of Lipitor, the top pharmaceutical product on the market, along with their previously noted desire to push forward into vaccines & biologics. Is this a good move for Pfizer? We believe that it is. The “new” Pfizer will gain access to several blockbusters, such as Enbrel…
The speculation that started last year and then reappeared last week surrounding a possible major acquisition by Pfizer has come to a close. This morning Pfizer announced that it plans to acquire Wyeth for $68 billion. There were several reasons why Pfizer would look to make an acquisition such as this. Two of these include Pfizer’s need to compensate for the impending patent loss of Lipitor, the top pharmaceutical product on the market, along with their previously noted desire to push forward into vaccines & biologics. Is this a good move for Pfizer? We believe that it is. The “new” Pfizer will gain access to several blockbusters, such as Enbrel…
27-Aug-2010
According to eHealth Forum’s latest survey more than half the respondents were NOT intending to get vaccinated against the flu virus this year… And for those that do, it might still be too late…
According to eHealth Forum’s latest survey more than half the respondents were NOT intending to get vaccinated against the flu virus this year… And for those that do, it might still be too late… One of the world’s largest health sites, www.ehealthforum.com just completed its annual survey about attitudes to the flu virus. The results clearly show that underlying – yet vital – messages are still not getting through. Over half the people surveyed (58.57%) were not planning to get the flu vaccine at all and almost 16 percent (15.96%) of the sample were unclear if the jab is recommended for them or wh…
According to eHealth Forum’s latest survey more than half the respondents were NOT intending to get vaccinated against the flu virus this year… And for those that do, it might still be too late… One of the world’s largest health sites, www.ehealthforum.com just completed its annual survey about attitudes to the flu virus. The results clearly show that underlying – yet vital – messages are still not getting through. Over half the people surveyed (58.57%) were not planning to get the flu vaccine at all and almost 16 percent (15.96%) of the sample were unclear if the jab is recommended for them or wh…
27-Aug-2010
Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice between portfolio diversification versus new product development.
2009 Pharmaceutical Industry Outlook Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice between portfolio divers…
2009 Pharmaceutical Industry Outlook Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice between portfolio divers…
27-Aug-2010
Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice between portfolio diversification versus new product development.
January 12th, 2009 2009 Pharmaceutical Industry Outlook Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice betwe…
January 12th, 2009 2009 Pharmaceutical Industry Outlook Ten years from now the pharmaceutical industry is going to be a very different industry than it is today; and looking back from that point we will see that the foundation for many of the changes to the pharmaceutical business model were laid in 2009. In Part One of a four part commentary on the outlook for 2009, we focus on the choice betwe…
The World Dermatological Market Outlook, 2009-2023
This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. This report will outline the developments and explain their significance. All the main dermatological market segments achieved positive sales growth from mid 2007 to mid 2008, giving hope for further gains. Dermatitis, anti-infectives and anti-acne treatments ranked as the top three therapeuti…
This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. This report will outline the developments and explain their significance. All the main dermatological market segments achieved positive sales growth from mid 2007 to mid 2008, giving hope for further gains. Dermatitis, anti-infectives and anti-acne treatments ranked as the top three therapeuti…
Pharma bigwigs confirm to speak in India’s biggest event in pharma:
More than 40 Industry leaders will chart the course ahead for the Indian Pharmaceutical and allied Industries
Bangalore will be adding one more feather to its cap. It will soon be playing to host another national event of high importance “The Pharmaceutical Leadership Summit 2009”, to be held at the Hotel Le Meredien on January 24th. The one day summit is being organized with a view to bring together leaders from the industry and crystallize their views and thoughts and assist the industry to find solutions and strategies to help the Indian pharma industry face challenges adroitly and seize opportunities as they arise. The who’s who of pharma industry led by Bangalore’s own Kiran Mazumdar of Biocon Lid, Kewal Handa of…
Bangalore will be adding one more feather to its cap. It will soon be playing to host another national event of high importance “The Pharmaceutical Leadership Summit 2009”, to be held at the Hotel Le Meredien on January 24th. The one day summit is being organized with a view to bring together leaders from the industry and crystallize their views and thoughts and assist the industry to find solutions and strategies to help the Indian pharma industry face challenges adroitly and seize opportunities as they arise. The who’s who of pharma industry led by Bangalore’s own Kiran Mazumdar of Biocon Lid, Kewal Handa of…
With more than 20,000 students, Kingston University is the largest provider of higher education in South West London, offering an extensive range of undergraduate and postgraduate programmes both in the United Kingdom and overseas. The University is renowned for teaching excellence, has established itself as a growing force in research and is widely respected as a pioneer in e-learning.
The first batch of students to complete Kingston University’s new Masters in Pharmacy has picked up their degrees. The awards, which were handed out in a special ceremony at Kingston’s Rose Theatre, marked a major milestone for the University’s School of Pharmacy and Chemistry which launched the MPharm four years ago. Thirty-six students graduated, with five scoring first class honours, and 24 gaining upper…
The first batch of students to complete Kingston University’s new Masters in Pharmacy has picked up their degrees. The awards, which were handed out in a special ceremony at Kingston’s Rose Theatre, marked a major milestone for the University’s School of Pharmacy and Chemistry which launched the MPharm four years ago. Thirty-six students graduated, with five scoring first class honours, and 24 gaining upper…
27-Aug-2010
This feature has been provided by Jonathan Hart-Smith, Managing Director of CK Clinical Limited.
The feature contains useful information for rapport buliding.
If you form a bond with people, and they feel an affinity with you, you will have stronger, more effective and enjoyable relationships. Even if your interaction is brief, whether it be dealing with a customer, a colleague or even attending a job interview you can get more out of the situation if you feel a shared purpose. I hope this article will serve to outline some basic techniques for forming a rapport quickly. Some people say that rapport is formed in the first minute and a half. We are all familiar with the expression “first impressions count” and like it or not, it’s true. When you meet somebody face to face or talk to th…
If you form a bond with people, and they feel an affinity with you, you will have stronger, more effective and enjoyable relationships. Even if your interaction is brief, whether it be dealing with a customer, a colleague or even attending a job interview you can get more out of the situation if you feel a shared purpose. I hope this article will serve to outline some basic techniques for forming a rapport quickly. Some people say that rapport is formed in the first minute and a half. We are all familiar with the expression “first impressions count” and like it or not, it’s true. When you meet somebody face to face or talk to th…
27-Aug-2010
This feature has been provided by Jonathan Hart-Smith,
Managing Director of CK Clinical Limited.
The feature contains useful information for Hiring Managers.
Imagine setting off on a journey. If you don’t know where you are going you will never get there. Before you read a CV for an applicant you need to consider how this role fits into your team, what job you want them to do and the type of person you are looking for. You can then plan the interview and decide on the type of questions you would like to ask. If you don’t have a job description and person specification then it is important to take some time to write one. Its is important for a candidate to make a good impression on you but you also need to make a good impression on them. In the current climate candidates have a lot…
Imagine setting off on a journey. If you don’t know where you are going you will never get there. Before you read a CV for an applicant you need to consider how this role fits into your team, what job you want them to do and the type of person you are looking for. You can then plan the interview and decide on the type of questions you would like to ask. If you don’t have a job description and person specification then it is important to take some time to write one. Its is important for a candidate to make a good impression on you but you also need to make a good impression on them. In the current climate candidates have a lot…
- Dossier admits UK biotech at breaking point.
- Sector can still flourish – but needs major investment.
- Industry calls for new investment partnership with government.
- Creation of two new investment super funds critical to future success.
Leading figures from the UK biotechology sector have presented the government with a dossier which identifies the need for ‘seismic’ change to save and transform the industry. Click here to download the dossier Twenty-two biotech leaders, including prominent biotech chairmen, chief executives, brokers and investors signed the dossier which has had inputs from over 50 different British biotech experts. It was recently sent to the Prime Minister and the Business Secretary, Lord Mandelson. The business leaders have been assessing the industry’s ne…
Leading figures from the UK biotechology sector have presented the government with a dossier which identifies the need for ‘seismic’ change to save and transform the industry. Click here to download the dossier Twenty-two biotech leaders, including prominent biotech chairmen, chief executives, brokers and investors signed the dossier which has had inputs from over 50 different British biotech experts. It was recently sent to the Prime Minister and the Business Secretary, Lord Mandelson. The business leaders have been assessing the industry’s ne…
27-Aug-2010
Paul Hartigan reports from the Financial Times Pharmaceutical Conference: London December 2nd and 3rd 2008
At the Financial Times Pharmaceutical Conference, David Brennan, CEO of AstraZeneca, gave the key note address , and issued what might be seen as a warning for those that see Big Pharma as a counter-cyclical safe-haven for investors, saying that it's true people need healthcare regardless of the economy," the economic recession will be " And the evidence is there that Big Pharma is imbibing some cost cutting medicine, with most of the major players reducing sales and marketing expenses, quite often through cuts in the sales force. But it could also be that the massive spend on DTC advertising (which is legal only in the USA and New Zealand will also see some diminution). According to…
At the Financial Times Pharmaceutical Conference, David Brennan, CEO of AstraZeneca, gave the key note address , and issued what might be seen as a warning for those that see Big Pharma as a counter-cyclical safe-haven for investors, saying that it's true people need healthcare regardless of the economy," the economic recession will be " And the evidence is there that Big Pharma is imbibing some cost cutting medicine, with most of the major players reducing sales and marketing expenses, quite often through cuts in the sales force. But it could also be that the massive spend on DTC advertising (which is legal only in the USA and New Zealand will also see some diminution). According to…
27-Aug-2010
Awards for Innovation, Export Achievement and NHS Partnership held at ERBI's Winter Ball at The Imperial War Museum, Duxford on November 29th 2008.
A project which has the capability to shorten patient waiting lists for CT scans used to detect life-threatening conditions such as brain tumours, has won Hope Enterprises the ERBI Medtech 2008 award for NHS Partnership, sponsored by Health Enterprise East. The team worked closely with NHS staff to capture the data needed for specially customised prediction software. The software demonstrated that a ‘zero wait’ can be achieved and a same day service offered to patients, thereby avoiding the need for a return journey to hospital. The award was presented to Roger Thorpe, Managing Director of Hope Enterprises by Barnaby Perks of ERBI Medtech, an…
A project which has the capability to shorten patient waiting lists for CT scans used to detect life-threatening conditions such as brain tumours, has won Hope Enterprises the ERBI Medtech 2008 award for NHS Partnership, sponsored by Health Enterprise East. The team worked closely with NHS staff to capture the data needed for specially customised prediction software. The software demonstrated that a ‘zero wait’ can be achieved and a same day service offered to patients, thereby avoiding the need for a return journey to hospital. The award was presented to Roger Thorpe, Managing Director of Hope Enterprises by Barnaby Perks of ERBI Medtech, an…
27-Aug-2010
‘More universities should provide courses that offer hands-on experience to better prepare their students.’ This is the response from the Head of Cranfield Health, Professor Joe Lunec, after a report claimed that those leaving universities lacked the required knowledge and skills to progress in the UK’s pharmaceutical industry.
The report released by the ABPI (The Association of British Pharmaceutical Industry) earlier this month suggested that the industry was at ‘tipping point’ due to those entering it not having enough laboratory or practical real-life experience. It also stated that the knowledge of research and development into new medicines was limited and highlighted a deficiency of skills in the critical subjects which support translational medicine leading to research trials in pat…
The report released by the ABPI (The Association of British Pharmaceutical Industry) earlier this month suggested that the industry was at ‘tipping point’ due to those entering it not having enough laboratory or practical real-life experience. It also stated that the knowledge of research and development into new medicines was limited and highlighted a deficiency of skills in the critical subjects which support translational medicine leading to research trials in pat…
27-Aug-2010
Our eMarketing team at PharmiWeb Solutions often works with pharma brand teams to find new ways to reach healthcare professionals with news of the latest product or initiative. And sometimes, it can be challenging, with all of the pressures and time constraints that the average primary care practice faces.
But surely it must be easier for patients? Well, we thought so too, until we came across this recent news story that may be the start of an alarming trend. According to veritable news source Newsbiscuit.com, Moira Braithwaite, 52, of Dorking, Surrey, UK is celebrating her ninth successive Receptionist of the Month Award after preventing over 35,000 patients getting an appointment within 48 hours during the month of September alone. Click here to find out more. Let us know if you’ve come a…
But surely it must be easier for patients? Well, we thought so too, until we came across this recent news story that may be the start of an alarming trend. According to veritable news source Newsbiscuit.com, Moira Braithwaite, 52, of Dorking, Surrey, UK is celebrating her ninth successive Receptionist of the Month Award after preventing over 35,000 patients getting an appointment within 48 hours during the month of September alone. Click here to find out more. Let us know if you’ve come a…
It takes courage to invest €300 million in a production site during a time of financial turmoil”,pointed out Karl-Ludwig Kley, Executive Board Chairman of the pharmaceutical company Merck Serono, this week.
The company, which is part of Merck KGaA, announced in the midst of the world’s greatest global economic downturn it had just made the biggest single investment in its corporate history. On top of the €1 billion it spends on R&D each year, hundreds of millions of euros are being ploughed into the construction of a state-of-the art facility to produce the company’s current and future biotechnology products. The existing site, where Merck Serono has produced its multiple sclerosis biotech product Rebif since 1999, has already achieved the ISO1401 international standard for environment…
The company, which is part of Merck KGaA, announced in the midst of the world’s greatest global economic downturn it had just made the biggest single investment in its corporate history. On top of the €1 billion it spends on R&D each year, hundreds of millions of euros are being ploughed into the construction of a state-of-the art facility to produce the company’s current and future biotechnology products. The existing site, where Merck Serono has produced its multiple sclerosis biotech product Rebif since 1999, has already achieved the ISO1401 international standard for environment…
27-Aug-2010
White paper from CERAM highlights novel techniques to expose fake medicines and unlicensed manufacturing processes
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved. The author of the white paper, Dr. Justine Bentley, explains how technology is helping to stem the trade in counterfeit drugs. She says "Counterfeit medicines are incredibly dangerous and represent a significant challenge to public health, so…
CERAM Surface and Materials Analysis has published a white paper highlighting how surface analysis can expose counterfeit medicines. It describes how technologies such as X-ray photoelectron spectroscopy (XPS) and Time-of-Flight Secondary Ion Mass Spectroscopy (ToFSIMS) are being used in novel ways to not only analyse the composition of various pharmaceuticals, but also to determine differences in the manufacturing processes involved. The author of the white paper, Dr. Justine Bentley, explains how technology is helping to stem the trade in counterfeit drugs. She says "Counterfeit medicines are incredibly dangerous and represent a significant challenge to public health, so…
The UK’s success as a global centre of biomedical excellence is under threat in the long-term. A new report by the Association of the British Pharmaceutical Industry (ABPI) has highlighted serious concerns about the supply of skills that support the research and development of new medicines.
The report, Skills Needs for Biomedical Research: creating the pools of talent to win the innovation race, reveals that British students are lacking the core laboratory and mathematical skills for research and there is a deficit in the supply of critical subjects to support translational medicine - the process by which early research is translated into candidate medicines that can be tested on patients. Skills Needs for Biomedical Research is a follow up to the 2005 report by the ABPI, Sustaining The Sk…
The report, Skills Needs for Biomedical Research: creating the pools of talent to win the innovation race, reveals that British students are lacking the core laboratory and mathematical skills for research and there is a deficit in the supply of critical subjects to support translational medicine - the process by which early research is translated into candidate medicines that can be tested on patients. Skills Needs for Biomedical Research is a follow up to the 2005 report by the ABPI, Sustaining The Sk…
27-Aug-2010
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value.
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating pr…
The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. With a reported $49.9bn in revenues in 2007, the GI disorders market competes consistently with cardiovascular diseases and oncology for the top 3 therapeutic areas in terms of market value. In 2007, this sector contributed seven blockbuster drugs, four of which ranked among the top 20 highest revenue generating pr…
